Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Aeglea Bio Therapeutics Inc    AGLE

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
11/13/2017 11/14/2017 11/15/2017 11/16/2017 11/17/2017 Date
4.82(c) 4.54(c) 4.65(c) 4.74(c) 4.54(c) Last
62 552 74 919 59 700 33 802 31 117 Volume
-6.04% -5.81% +2.42% +1.94% -4.22% Change
More quotes
Financials ($)
Sales 2017 4,85 M
EBIT 2017 -29,7 M
Net income 2017 -29,4 M
Finance 2017 51,2 M
Yield 2017 -
Sales 2018 1,95 M
EBIT 2018 -38,8 M
Net income 2018 -38,3 M
Finance 2018 21,7 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales2017 5,03x
EV / Sales2018 27,6x
Capitalization 75,6 M
More Financials
Company
Aeglea Biotherapeutics, Inc. operates as a biopharmaceutical company, which engages in developing engineered human enzymes for the treatment of inborn errors of metabolism and cancer.It develops AEB1102, an amino acid for the degradation of arginine in the circulation, as well as for the treatment... 
More about the company
Surperformance© ratings of Aeglea Bio Therapeutics In
Trading Rating : Investor Rating :
More Ratings
Latest news on AEGLEA BIO THERAPEUTICS IN
11/07 AEGLEA BIO THERAPEUTICS : reports 3Q loss
11/07 AEGLEA BIOTHERAPEUTICS, INC. : Results of Operations and Financial Condition, Fi..
11/07 AEGLEA BIO THERAPEUTICS : BIOTHERAPEUTICS, INC. MANAGEMENT'S DISCUSSION AND ANAL..
11/07 AEGLEA BIO THERAPEUTICS : BioTherapeutics Provides Corporate Update and Reports ..
11/02 Aeglea BioTherapeutics to Present Preclinical Data at 2017 Society for Immuno..
10/16 Aeglea BioTherapeutics Announces Clinical Collaboration with Merck to Evaluat..
09/07 AEGLEA BIOTHERAPEUTICS, INC. : Change in Directors or Principal Officers (form 8..
09/07 AEGLEA BIO THERAPEUTICS : BioTherapeutics Doses Two Patients in Repeat Dose Part..
09/06 Aeglea BioTherapeutics Doses Two Patients in Repeat Dose Part of Phase 1/2 Cl..
08/31 Aeglea BioTherapeutics to Present at the 2017 Wells Fargo Healthcare Conferen..
More news
Sector news : Bio Therapeutic Drugs
11/16 Recovery rally for European stocks leaves oil sector behind
11/13 Poor earnings updates keep European shares at seven-week low
11/13DJNOVARTIS : Vision Drug Shows Positive Results in Phase 3 Trials
11/03 Prosecutors search Metro offices in insider trading probe
11/01DJAs Experimental Treatments Grow, Families Face Tough Choices
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
11/13 Aeglea Biotherapeutics (AGLE) Presents At Society For Immunotherapy Of Cancer..
11/07 Aeglea BioTherapeutics beats by $0.07, beats on revenue
09/08 HEALTHCARE GAINERS / LOSERS AS OF 11 : 00 am
08/09 Aeglea BioTherapeutics beats by $0.01, beats on revenue
08/05 Stocks to watch next week
Chart AEGLEA BIO THERAPEUTICS IN
Duration : Period :
Aeglea Bio Therapeutics In Technical Analysis Chart | AGLE | US00773J1034 | 4-Traders
Technical analysis trends AEGLEA BIO THERAPEUTICS IN
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Average target price 16,3 $
Spread / Average Target 258%
EPS Revisions
Managers
NameTitle
Anthony G. Quinn Chief Executive Officer & Director
Armen B. Shanafelt Chairman
Charles N. York Chief Financial Officer & Vice President
Scott W. Rowlinson Vice President-Research
James Wooldridge Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
AEGLEA BIO THERAPEUTICS INC4.37%76
GILEAD SCIENCES1.16%94 601
REGENERON PHARMACEUTICALS6.67%42 072
VERTEX PHARMACEUTICALS100.10%37 280
GENMAB3.15%11 878
EXELIXIS, INC.76.93%7 805